Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Journey Medical (DERM) EBITDA Margin: 2020-2024

Historic EBITDA Margin for Journey Medical (DERM) over the last 5 years, with Dec 2024 value amounting to -24.36%.

  • Journey Medical's EBITDA Margin rose 1111.00% to -8.67% in Q3 2025 from the same period last year, while for Sep 2025 it was -9.25%, marking a year-over-year increase of 2193.00%. This contributed to the annual value of -24.36% for FY2024, which is 2175.00% down from last year.
  • According to the latest figures from FY2024, Journey Medical's EBITDA Margin is -24.36%, which was down 830.65% from -2.62% recorded in FY2023.
  • In the past 5 years, Journey Medical's EBITDA Margin registered a high of 17.63% during FY2020, and its lowest value of -55.25% during FY2021.
  • Over the past 3 years, Journey Medical's median EBITDA Margin value was -24.36% (recorded in 2024), while the average stood at -21.45%.
  • In the last 5 years, Journey Medical's EBITDA Margin crashed by 7,288bps in 2021 and then soared by 3,473bps in 2023.
  • Over the past 5 years, Journey Medical's EBITDA Margin (Yearly) stood at 17.63% in 2020, then slumped by 7,288bps to -55.25% in 2021, then soared by 1,790bps to -37.35% in 2022, then skyrocketed by 3,473bps to -2.62% in 2023, then slumped by 2,175bps to -24.36% in 2024.